Scar ectopic in pregnancy
Reading File
Finding Sources
Finding Sources
Searching PubMed
"cesarean scar pregnancy" AND management
Searching the Web
cesarean scar ectopic pregnancy diagnosis management 2024 guideline
Reading File
Cesarean Scar (Scar) Ectopic Pregnancy
A cesarean scar pregnancy (CSP) is a pregnancy that implants within the myometrium at the site of a previous cesarean delivery scar. It is a distinct type of ectopic pregnancy (not intracavitary, not tubal) that carries serious risk if missed.
Epidemiology
- Incidence is rising as cesarean delivery rates increase, estimated around 1 in 500 pregnancies among women with a prior cesarean delivery (Berek & Novak's Gynecology, p. 1782).
- It isn't yet established whether the number of prior cesareans or incision type (classical vs. Pfannenstiel) changes risk.
Diagnosis
Transvaginal ultrasound is the first-line and primary diagnostic tool. Key sonographic features (Berek & Novak's Gynecology):
- Gestational sac located at the level of the prior cesarean scar
- Peritrophoblastic Doppler flow with minimal separation from the bladder
- Outward bulging of the gestational sac at the scar site
- Negative "sliding organs sign" - the sac does not move with gentle transvaginal probe pressure
CSPs are classified into two types by prognosis/growth direction:
- Type 1: progressing toward the uterine cavity (potentially viable but high risk of morbidly adherent placenta)
- Type 2: progressing toward the bladder/serosa (higher risk of early rupture and hemorrhage)
SMFM (reaffirmed 2024) and contemporary practice recommend early ultrasound evaluation between 5-10 weeks' gestation in anyone with a prior cesarean, and prompt referral if an anterior, low-lying gestational sac is seen.
Why It Matters
If undiagnosed or untreated, CSP can progress to placenta accreta spectrum or uterine rupture, both associated with severe maternal hemorrhage and morbidity. Early diagnosis and treatment are strongly recommended.
Management
No single approach has proven superior; treatment is individualized by type, gestational age, hemodynamic stability, and desire for future fertility. Reported approaches and outcomes (Berek & Novak's Gynecology):
| Approach | Success rate | Hemorrhage risk | Hysterectomy risk |
|---|---|---|---|
| Methotrexate (systemic) | 56% | - | - |
| Methotrexate (local injection) | 60% | - | - |
| Methotrexate (combined systemic + local) | 77% | 7% | 3% |
| D&C under ultrasound guidance | 76% | 30% | 3% |
| Methotrexate followed by D&C | up to 86% | 14% | 4% |
| Uterine artery embolization (UAE) alone | 81% | 5% | 4% |
- Medical management (methotrexate or KCl, systemic or local) is only appropriate for hemodynamically stable patients.
- Hysteroscopic resection carries a notably high (62%) risk of persistent trophoblastic tissue and is generally combined with D&C rather than used alone.
- UAE can be used prophylactically before D&C/methotrexate to reduce hemorrhage risk, or reactively if hemorrhage occurs.
- If the patient wishes to continue a viable CSP (rare, high-risk), SMFM's 2024-reaffirmed consult recommends planned repeat cesarean delivery at 34 0/7-35 6/7 weeks, with strong counseling on recurrence risk and effective contraception (including LARC or permanent contraception) afterward.
Recent Evidence (worth noting)
Several 2023-2025 systematic reviews refine this picture and may update parts of the older textbook data:
- Expectant/conservative management of viable CSPs has been systematically reviewed (Vieira de Mello et al. 2023, PMID 36394667; Silva et al. 2023, PMID 37421745) - showing that continuation is sometimes feasible but with substantial risks of accreta, hemorrhage, and preterm birth.
- Combined methotrexate + mifepristone conservative treatment reviewed in 2024 (PMID 39407415).
- A 2024 comprehensive review (PMID 38566372) surveys UAE, methotrexate, and surgical/hysteroscopic techniques with attention to fertility preservation.
- A 2025 systematic review specifically evaluates an exclusive hysteroscopic approach (PMID 41263088), suggesting evolving technique preferences beyond what's captured in the older textbook percentages above.
Given the rarity and heterogeneity of CSP, management should involve a clinician/center experienced with this condition, and decisions should be individualized rather than protocol-driven.
This is a shared conversation. Sign in to Orris to start your own chat.